Receive Email Updates
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
Category Archives: Non-U.S. Practice
IPO Letter Reports Weaknesses in IP Protection Around the World In a 27 page letter dated February 8, 2018 and sent to Sue Chang at the Office of the U.S. Trade Representative, the Executive Director of IPO, Mark Lauroesch, extensively … Continue reading
Although the Australian High Court held that claims to naturally occurring DNA (e.g., BRCA1 nucleic acid) were not patent eligible because they were not a “manner of manufacture,” since the encoded information therein was not “made” by human action, in … Continue reading
Provided to us by Dr. Stefan Danner of DHS Patentanwalts GmbH, find below the current issue of the biotech IP newsletter dealing with recent EPO case law on Article 123(2)(3) EPC. Extension Trap
Find below biotech IP newsletters recently provided by Dr. Stefan Danner. SPCs For Combination Products – Opinion Of The Advocate General EPO Ruling On The Patentability Of Medical Treatments By Therapy